Most Read Articles
13 Oct 2017
Use of systemic antibiotics, in conjunction with performance of incision and drainage, in the management of paediatric acute skin and soft tissue infection (SSTI) appears to reduce Staphylococcus aureus colonization and the likelihood of infection recurrence, a prospective study has found.
12 Oct 2017
Retreatment with ledipasvir and sofosbuvir with add-on ribavirin appears to be effective and well tolerated in genotype 1 hepatitis C virus (HCV)-infected patients who have failed to respond to daclatasvir/asunaprevir combination therapy, according to a study.
6 days ago
Excessive intake of the mineral manganese can be toxic to the heart, according to a new study.

Tedizolid may be effective in MRSA-associated skin infections

16 Mar 2017

The novel oxazolidinone tedizolid appears to be clinically superior to vancomycin and comparable with other monotherapy drugs in treating serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), according to a systematic review and network meta-analysis.

Tedizolid has been shown in phase III noninferiority trials to have a favourable tolerability profile and is as effective as linezolid against a wide range of Gram-positive pathogens in the treatment of acute bacterial skin and skin structure infections (ABSSSI). [Antimicrob Agents Chemother 2015;59:864-71]

A total of 10 databases were searched for eligible studies consisting of randomized clinical trials (RCTs) published in English that investigated the efficacy of tedizolid or other established antimicrobials (namely, vancomycin, linezolid, daptomycin, teicoplanin, tigecycline, ceftaroline or telavancin) as monotherapy in adults with suspected or documented MRSA-ABSSSI, or complicated skin and skin structure infections (cSSSI).

Outcome measures included clinical response rate at end of therapy (EOT), post-therapy evaluation (PTE) or test-of-cure (TOC) assessment as well as serious adverse events (AEs) leading to discontinuation of treatment.

Of the 3,618 identified records, 15 RCTs were included for analysis. Tedizolid was shown to be superior in terms of clinical response at EOT (odds ratio [OR], 1.7) and had higher odds of clinical response at PTE or TOC (OR, 1.6) compared with vancomycin, but not with other comparators. No difference was observed among all treatments for discontinuation due to AEs.

“These findings suggest that tedizolid provides an alternative option for the management of serious skin infections caused by suspected or documented MRSA,” said researchers, adding that caution must be observed in interpreting the study results.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
13 Oct 2017
Use of systemic antibiotics, in conjunction with performance of incision and drainage, in the management of paediatric acute skin and soft tissue infection (SSTI) appears to reduce Staphylococcus aureus colonization and the likelihood of infection recurrence, a prospective study has found.
12 Oct 2017
Retreatment with ledipasvir and sofosbuvir with add-on ribavirin appears to be effective and well tolerated in genotype 1 hepatitis C virus (HCV)-infected patients who have failed to respond to daclatasvir/asunaprevir combination therapy, according to a study.
6 days ago
Excessive intake of the mineral manganese can be toxic to the heart, according to a new study.